Mavik and Pregnancy Categories C and D

Because the results of the study explained above have not been confirmed, the U.S. Food and Drug Administration (FDA) categorizes Mavik as a pregnancy Category C medicine for the first trimester and a pregnancy Category D medicine for the second and third trimesters.

 

The FDA uses a pregnancy category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. Pregnancy Category C is given to medicines that have not been studied in pregnant humans but show side effects to the fetus in animal studies. Pregnancy Category D is given to medicines that have shown clear evidence of risk to the fetus in studies. It is a stronger warning than for pregnancy Category C medicines. Despite these warnings, a pregnancy Category C or D medicine may still be given to a pregnant woman if her healthcare provider believes that its benefits outweigh the possible risks to her unborn child.

 

Mavik and Pregnancy: Recommendations

Because of the possible risk that Mavik poses to an unborn child even during the first trimester of pregnancy, you should be sure to let your healthcare provider know, prior to taking Mavik, if you are pregnant or thinking of becoming pregnant. Your healthcare provider will consider both the benefits and risks of Mavik during pregnancy before making a recommendation for your particular situation. In all but the rarest of situations, there are other options for women who are pregnant or could become pregnant.